IV peramivir may get swift approval

There's been a considerable amount of speculation about which of the new flu vaccine and antiviral technologies now in the clinic will benefit from the swine flu outbreak and the outcry it has provoked for better medicines. Most of that speculation has centered on future pandemics--but BioCryst may not have to wait that long. While HHS Secretary Kathleen Sebelius was being grilled about shortages of vaccines and antivirals, she voiced a strong desire to see the intravenous formulation of BioCryst's antiviral peramivir approved quickly. BioCryst report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.